SwePub
Sök i LIBRIS databas

  Extended search

id:"swepub:oai:DiVA.org:uu-342579"
 

Search: id:"swepub:oai:DiVA.org:uu-342579" > High doses of chole...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Westerberg, Per-Anton,1967-Uppsala universitet,Njurmedicin,County Hospital, Jönköping, Sweden (author)

High doses of cholecalciferol alleviate the progression of hyperparathyroidism in patients with CKD Stages 3-4 : results of a 12-week double-blind, randomized, controlled study

  • Article/chapterEnglish2018

Publisher, publication year, extent ...

  • 2017-05-30
  • Oxford University Press (OUP),2018
  • electronicrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:uu-342579
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-342579URI
  • https://doi.org/10.1093/ndt/gfx059DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Background: Calcidiol insufficiency may accelerate the development of secondary hyperparathyroidism (SHPT). We tested the effect of a substantial increase in calcidiol on mineral metabolism in patients with chronic kidney disease (CKD).Methods: Ninety-five patients with CKD Stages 3-4, parathyroid hormone (PTH) above 6.8 pmol/L and calcidiol below 75 nmol/L were randomized to receive either cholecalciferol 8000 IU/day or placebo for 12 weeks. The primary endpoint was difference in the mean change in iPTH after 12 weeks. The proportion of participants having a 30% reduction in PTH and the effect on hand grip strength, fatigue and different biochemical variables were also investigated.Results: Baseline calcidiol was 57.5 ± 22 and 56.8 ± 22 nmol/L in the cholecalciferol and placebo groups, respectively. The corresponding concentrations of PTH were 10.9 ± 5 and 13.1 ± 9 pmol/L. Calcidiol increased to 162 ± 49 nmol/L in patients receiving cholecalciferol, and PTH levels remained constant at 10.5 ± 5 pmol/L. In the placebo group, calcidiol remained stable and PTH increased to 15.2 ± 11 pmol/L. The mean change in PTH differed significantly between the two groups (P < 0.01). The proportion of subjects reaching a 30% decrease in PTH did not differ. No effect on grip strength, fatigue, phosphate or fibroblast growth factor 23 was observed. Cholecalciferol treatment resulted in stable calcium concentrations and a substantial increase in calcitriol.Conclusion: Treatment with high daily doses of cholecalciferol in patients with CKD Stages 3-4 halts the progression of SHPT and does not cause hypercalcaemia or other side effects.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Sterner, Gunnar (author)
  • Ljunggren, ÖstenUppsala universitet,Endokrinologi och mineralmetabolism(Swepub:uu)osteljun (author)
  • Isaksson, Elin (author)
  • Elvarson, FjölnirUppsala universitet,Institutionen för medicinska vetenskaper(Swepub:uu)fjoel918 (author)
  • Dezfoolian, Hamid (author)
  • Linde, TorbjörnUppsala universitet,Njurmedicin(Swepub:uu)torblind (author)
  • Uppsala universitetNjurmedicin (creator_code:org_t)

Related titles

  • In:Nephrology, Dialysis and Transplantation: Oxford University Press (OUP)33:3, s. 466-4710931-05091460-2385

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view